Skip to Main Content

Paper Details

Multi-antigen-targeted T-cell therapy to treat patients with relapsed/refractory breast cancer.
Therapeutic Advances in Medical Oncology
5
2022
BC, MAGE, MAGE-A4, MultiTAA T cells, NY-ESO-1, PRAME, Patients, SSX2, Survivin, T, T cells, T-cell, T-cell products, breast cancer, estrogen, estrogen receptor, human, human epidermal growth factor receptor 2, multi-antigen-targeted T cells, multiTAA T cells, multiTAA-T, patient, patients, progesterone, progesterone receptor, relapsed/refractory
Author NameAffiliation
Matthew J EllisDan L Duncan Comprehensive Cancer Center, Baylor College of Medicine
Charles Kent OsborneDan L Duncan Comprehensive Cancer Center, Baylor College of Medicine
Julie NangiaDan L Duncan Comprehensive Cancer Center, Baylor College of Medicine
Mothaffar F RimawiDan L Duncan Comprehensive Cancer Center, Baylor College of Medicine
  • 1 - 4

Datasets

Release 1.2